本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603648 证券简称：畅联股份 公告编号：2025-031 上海畅联国际物流股份有限公司 第四届监事会第十二次会议决议公告 2025 年 12 月 2 日 一、监事会会议召开情况 上海畅联国际物流股份有限公司（以下简称"公司"）第四届监事会第十二 次会议于 2025 年 11 月 28 日在公司会议室以通讯表决的方式召开。会议通知及会 议材料于 2025 年 11 月 14 日以电子邮件、电话等形式发出。本次会议由监事会主 席李健飞先生主持，应出席监事 5 名，实际出席监事 5 名。会议参与表决人数及 召集、召开程序符合《公司法》和《公司章程》的有关规定，所作决议合法有效。 本议案尚需提交公司股东大会审议。在公司股东大会审议通过取消监事会事 项之前，公司第四届监事会仍将严格按照有关法律、行政法规和《公司章程》的 规定继续履行监督职能，维护公司和全体股东利益。 表决结果：5 票赞成、0 票反对、0 票弃权，0 票回避表决。 特此公告。 上海畅联国际物流股份有限公司监事会 ...

证券代码：603648 证券简称：畅联股份 公告编号：2025-030 上海畅联国际物流股份有限公司 第四届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海畅联国际物流股份有限公司（以下简称"公司"）第四届董事会第十四 次会议于 2025 年 11 月 28 日在公司会议室以通讯表决方式召开。会议通知及会议 材料于 2025 年 11 月 14 日以电子邮件、电话等形式发出。本次会议由董事长尹强 先生主持，应出席董事 11 名，实际出席董事 11 名。会议参与表决人数及召集、 召开程序符合《公司法》和《公司章程》的有关规定，所作决议合法有效。 二、董事会会议审议情况 本次董事会会议审议并通过了以下议案： 1、审议通过了《关于取消监事会、修订<公司章程>暨新增、修订部分治理制 度的议案》 为完善公司治理，确保符合上市公司规则要求，根据相关法律、行政法规及 其他规范性文件的最新规定，结合公司实际情况，同意修订《公司章程》，拟不 再设置监事会，由董事会审计委员会行使《公司法》规 ...

2024年1至12月份，畅联股份的营业收入构成为：供应链管理占比99.99%，其他业务占比0.01%。 截至发稿，畅联股份市值为38亿元。 每经AI快讯，畅联股份（SH 603648，收盘价：10.48元）12月1日晚间发布公告称，公司第四届第十四 次董事会会议于2025年11月28日在公司会议室以通讯表决方式召开。会议审议了《关于确认公司第五届 董事领取薪酬或津贴的议案》等文件。 每经头条（nbdtoutiao）——5年期大面积下线，3年期利率低至1.5%仍一单难求：要么"售罄"要么"额度 紧张"！中长期大额存单为何在消失？ （记者 王晓波） ...

证券代码：603648 证券简称：畅联股份 公告编号：2025-029 上海畅联国际物流股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 12 月 05 日 （星期五） 10:00-11:00 （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 28 日 （星期五） 至 12 月 04 日 （星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海畅联国际物流 股份有限公司（以下简称"公司"）邮箱（investor-relations@chinaslc.com） 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 上海畅联国际物流股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 ...

Company Overview - Changlian Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 22, 2001. The company was listed on September 13, 2017. Its main business involves providing lean supply chain management services to multinational enterprises [1]. - The revenue composition of Changlian Co., Ltd. is as follows: Supply Chain Logistics 99.85%, Supply Chain Trade 0.11%, and Others 0.04% [1]. Financial Performance - For the period from January to September 2025, Changlian Co., Ltd. achieved an operating income of 1.137 billion yuan, a year-on-year decrease of 10.64%. The net profit attributable to the parent company was 91.2642 million yuan, down 18.85% year-on-year [2]. - Since its A-share listing, Changlian Co., Ltd. has distributed a total of 714 million yuan in dividends, with 362 million yuan distributed over the past three years [3]. Stock Performance - As of November 27, Changlian Co., Ltd.'s stock price increased by 2.45%, reaching 10.47 yuan per share, with a total market capitalization of 3.794 billion yuan [1]. - Year-to-date, the stock price has risen by 5.12%, but it has seen declines of 1.41% over the last five trading days, 3.59% over the last 20 days, and 5.33% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on August 7, where it recorded a net purchase of 39.9407 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders of Changlian Co., Ltd. was 20,400, a decrease of 4.98% from the previous period. The average circulating shares per person increased by 5.24% to 17,797 shares [2]. - Among the top ten circulating shareholders, the China Securities Shanghai State-owned Enterprise ETF (510810) has exited the list [3]. Industry Context - Changlian Co., Ltd. operates within the transportation and logistics sector, specifically in the intermediate products and consumer goods supply chain services. It is associated with concepts such as unified market, free trade port, Yangtze River Delta integration, Shanghai state-owned assets, and smart logistics [2].

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - Changlian Co., Ltd. will invest 30 million yuan, accounting for 60% of the registered capital of the new company [1] - The registered capital of the new company is set at 50 million yuan, with a profit distribution ratio of no less than 60% of the annual net profit [1] - The investment is expected to be completed by January 30, 2026 [1]

Core Points - On November 12, Century Huatong announced a share repurchase plan of 500 million to 1 billion yuan for capital reduction [1][2] - A total of 18 A-share listed companies disclosed share reduction plans, indicating a trend of shareholder divestment [1][2] Summary of Share Repurchase - Century Huatong plans to repurchase shares worth between 500 million and 1 billion yuan to reduce registered capital [2] Summary of Share Reductions - Tai Xiang Co. plans to reduce no more than 1% of its shares by shareholder Zhongyuan Investment [2] - Jiang Bolong's second-largest shareholder has completed a reduction of 4.1915 million shares [2] - Senior management of Zhejiang Zhongcheng plans to reduce their holdings [2] - Controlling shareholder of Hexing Packaging intends to reduce no more than 1.91% of shares [2] - Shareholder Wang Ge of Dongfang Zhongke plans to reduce no more than 0.51% of shares [2] - Executive Yu Qingchi of Kuai Publishing plans to reduce no more than 0.02% of shares [2] - Directors and executives of Changlian Co. plan to collectively reduce no more than 0.77% of shares [2] - China Unicom's structural adjustment fund reduced 40.7003 million shares from November 10 to November 12 [2] - Shareholder Chen Bei of Ruimaite plans to reduce no more than 1.76% of shares [2] - Shareholder Zhang Hong of Aipeng Medical plans to reduce no more than 2% of shares [2] - Director Wo Jinye of Jujiao Co. plans to reduce no more than 0.01% of shares [2] - Directors and executives of Zhonglan Environmental Protection plan to reduce their holdings [2] - Shareholders Ning Kangqi and Beikangqi of Hendi Pharmaceutical plan to collectively reduce no more than 2.33% of shares [2] - Wuxi High-tech Zone New Momentum Industry Development Fund reduced 549,200 shares of Xiangnan Chip [2] - Controlling shareholder of Tianji Co. sold 8.4 million shares during a period of significant stock trading volatility [2] - The second-largest shareholder of Fangzheng Electric reduced a total of 1.6324 million shares on November 10 and 12 [2] - Controlling shareholder of Haodangjia plans to reduce no more than 2.7% of shares [2] - Controlling shareholder of Zhibang Home reduced 905,000 convertible bonds [2]

Summary of Key Points Core Viewpoint - The article discusses various companies and their shareholders' intentions to buy or sell shares, indicating a trend of both increasing and decreasing shareholdings among different firms in the market [1]. Company Actions - 康缘药业's actual controller's concerted action party increased holdings by 80,000 shares [1]. - 好当家's controlling shareholder plans to reduce holdings by no more than 2.7% [1]. - 亨迪药业's shareholders, including 宁康企管, 倍康企管, and 雷小艳, intend to collectively reduce holdings by no more than 2.33% [1]. - 合兴包装's controlling shareholder 新疆兴汇聚 plans to reduce holdings by no more than 1.91% [1]. - 瑞迈特's shareholder 陈蓓 intends to reduce holdings by no more than 1.76% [1]. - 泰祥股份's 众远投资 plans to reduce holdings by no more than 1% [1]. - 香农芯创's 无锡高新区新动能产业发展基金 reduced holdings by 549,200 shares [1]. - 中国联通's structural adjustment fund will reduce holdings by 40,700,300 shares from November 10 to November 12 [1]. - 方正电机's shareholder 张敏 reduced holdings by 1,632,400 shares [1]. - 畅联股份's directors 徐峰 and 陈文晔 plan to reduce holdings by 0.57% and 0.20%, respectively [1]. - 中兰环保's shareholders 王广庆, 曹丽, and 李泉 plan to reduce holdings by 0.0375%, 0.2798%, and 0.0275%, respectively [1]. - 聚胶股份's director 沃金业 plans to reduce holdings by 0.01% [1]. - 浙江众成's executives 黄旭生 and 潘德祥 plan to reduce holdings by 0.0140% [1]. - 东方中科's shareholder 王戈 plans to reduce holdings by 0.51% [1]. - 海南瑞泽's vice president 于清池 plans to reduce holdings by no more than 0.02% [1].

Core Viewpoint - Changlian Co., Ltd. (603648.SH) announced plans for share reduction by key executives, indicating potential changes in insider ownership and market sentiment [1] Group 1: Executive Share Reduction Plans - The company's General Manager, Mr. Xu Feng, plans to reduce his holdings by up to 2.0652 million shares, representing 0.57% of the total share capital [1] - The company's Deputy General Manager, Ms. Chen Wenye, intends to reduce her holdings by up to 736,400 shares, accounting for 0.20% of the total share capital [1] - Both reductions will occur through centralized bidding on the Shanghai Stock Exchange within a specified period from December 4, 2025, to March 3, 2026 [1]